|
Oct 10
|
Kuros Reports 149% Increase in Direct MagnetOs Sales and Exceeds Cash Flow Breakeven in the First Nine Months of 2024
|
|
Jun 25
|
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft
|
|
Dec 27
|
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
|
|
Nov 28
|
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
|